Cardiovascular Toxicity With Cisplatin in Patients With Testicular Cancer

Figure 1. Risk of Vascular Disease and Events in Patient With Testicular Cancer Patients with testicular cancer are at risk of vascular disease and events. Those with higher-dose cisplatin therapy face a higher acute and potentially long-term risk. Cardiovascular risk factors (CVRFs) and cardiovascular diseases (CVD) set a baseline risk level, and the acute risk with cancer therapy remains variable in extent and duration. Conceivably some patients show complete reversibility to baseline levels but others do not. The long-term risk is illustrated as a linear risk model, but may differ in reality and is influenced by various factors in the individual patient. Vasoreactivity testing in particular seems to be well suited to follow patients across this continuum of care and possibly to gauge the need and benefit of therapeutic interventions. CV = cardiovascular; vWF Ag = von Willebrand factor antigen.